SOLENO THERAPEUTICS INC(SLNO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

SOLENO THERAPEUTICS INC (SLNO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SLNO at 52.2/100 on a 32-signal composite quality model, placing it at rank #1,476 of 2,962 stocks — the top half of the AI-ranked universe. SLNO scores in the top quartile across revenue growth (97.1), balance sheet strength (96.4). Areas of concern include profitability (30.0) and free cash flow (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SOLENO THERAPEUTICS INC reports quarterly revenue of $94.6M, net income of $31.4M, an operating margin of 33.1%. Top institutional holders of SLNO by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, BlackRock, based on the most recent SEC filings. SLNO trades on the Nasdaq exchange and files with the SEC under CIK 1484565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLNO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SOLENO THERAPEUTICS INC directly from SEC EDGAR.